OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Persistence of Antibodies Six Months after Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease
Freddy Caldera, Luke J. Richard, Mazen Almasry, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 10, pp. 1662-1666
Open Access | Times Cited: 8
Freddy Caldera, Luke J. Richard, Mazen Almasry, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 10, pp. 1662-1666
Open Access | Times Cited: 8
Showing 8 citing articles:
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.
Trevor L. Schell, Freddy Caldera
PubMed (2024) Vol. 20, Iss. 2, pp. 88-97
Closed Access | Times Cited: 2
Trevor L. Schell, Freddy Caldera
PubMed (2024) Vol. 20, Iss. 2, pp. 88-97
Closed Access | Times Cited: 2
COVID-19 vaccination in adults with inflammatory bowel disease
Megan Lutz, Sarah Lazarus, Freddy Caldera
Therapeutic Advances in Gastroenterology (2023) Vol. 16, pp. 175628482311731-175628482311731
Open Access | Times Cited: 2
Megan Lutz, Sarah Lazarus, Freddy Caldera
Therapeutic Advances in Gastroenterology (2023) Vol. 16, pp. 175628482311731-175628482311731
Open Access | Times Cited: 2
Impacto de la mesalazina en la respuesta a la vacunación contra la COVID-19 en pacientes con enfermedad inflamatoria intestinal. Resultados de un estudio prospectivo multicéntrico de GETECCU (VACOVEII)
Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 7, pp. 750-758
Closed Access
Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 7, pp. 750-758
Closed Access
Higher and Sustained Cell-Mediated Immune Responses after Three Doses of mRNA COVID-19 Vaccine In Patients with Inflammatory Bowel Disease on Anti-TNF Therapy
Freddy Caldera, Stacey Rolak, Francis A. Farraye, et al.
Clinical and Translational Gastroenterology (2024)
Open Access
Freddy Caldera, Stacey Rolak, Francis A. Farraye, et al.
Clinical and Translational Gastroenterology (2024)
Open Access
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)
Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 7, pp. 750-758
Closed Access
Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 7, pp. 750-758
Closed Access
SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection
Alice Hoyois, C Gulkilik, Leila Mekkaoui, et al.
Acta Gastro Enterologica Belgica (2024) Vol. 87, Iss. 2, pp. 263-273
Closed Access
Alice Hoyois, C Gulkilik, Leila Mekkaoui, et al.
Acta Gastro Enterologica Belgica (2024) Vol. 87, Iss. 2, pp. 263-273
Closed Access
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 8, pp. 821-833
Closed Access
Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 8, pp. 821-833
Closed Access
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Gastroenterología y Hepatología (2023) Vol. 47, Iss. 8, pp. 821-833
Closed Access
Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Gastroenterología y Hepatología (2023) Vol. 47, Iss. 8, pp. 821-833
Closed Access
